Lenvatinib and Its Use in the Treatment of Unresectable Hepatocellular Carcinoma

Future Oncology - United Kingdom
doi 10.2217/fon-2017-0689
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Pcn188 - Assessing the Robustness of a Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib in Unresectable Hepatocellular Carcinoma in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Carnitine Insufficiency Is Associated With Fatigue During Lenvatinib Treatment in Patients With Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2020English

Gender-Based Outcomes Differences in Unresectable Hepatocellular Carcinoma

Hepatology International
Hepatology
2007English

Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Journal of Gastroenterology
Gastroenterology
2016English

Regional Differences in Hepatocellular Carcinoma and Its Surgical Treatment

HPB Surgery
SurgeryHepatology
1991English

Multimodality Treatment With Conventional Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma

Digestion
Gastroenterology
2012English

Network Meta-Analysis of Treatments for Unresectable Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination With Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy